The relationship of APOE genotype to neuropsychological performance in long-term cancer survivors treated with standard dose chemotherapy

Tim A. Ahles, Andrew Saykin, Walter W. Noll, Charlotte T. Furstenberg, Stephen Guerin, Bernard Cole, Leila A. Mott

Research output: Contribution to journalArticle

210 Citations (Scopus)

Abstract

Purpose: The primary purpose of this study was to compare the neuropsychological performance of long-term survivors of breast cancer and lymphoma treated with standard dose chemotherapy who carried the ε4 allele of the Apolipoprotein E (APOE) gene to those who carry other APOE alleles. Patients and methods: Long-term survivors (mean = 8.8 ± 4.3 years post-treatment) of breast cancer (N = 51, age = 55.9 ± 8.8) or lymphoma (N = 29, age = 55.8 ± 11.6) who had been treated with standard-dose chemotherapy completed a standardized battery of neuropsychological and psychological tests. Survivors were also classified into two groups based on the presence (N = 17) or absence (N = 63) of at least one ε4 allele of APOE. Results: Analysis of covariance, controlling for age, gender, education, diagnosis, and WRAT-3 reading subtest (a proxy measure of baseline IQ), indicated that survivors with at least one ε4 allele scored significantly lower in the visual memory (p <0.03) and the spatial ability (p <0.05) domains and tended to score lower in the psychomotor functioning (p <0.08) domain as compared to survivors who did not carry an ε4 allele. No group differences were found on depression, anxiety, or fatigue. Conclusions: The results of this study provide preliminary support for the hypothesis that the ε4 allele of APOE may be a potential genetic marker for increased vulnerability to chemotherapy-induced cognitive decline.

Original languageEnglish (US)
Pages (from-to)612-619
Number of pages8
JournalPsycho-Oncology
Volume12
Issue number6
DOIs
StatePublished - Sep 2003
Externally publishedYes

Fingerprint

Apolipoproteins E
Survivors
cancer
Alleles
Genotype
Apolipoprotein E4
Drug Therapy
performance
Neoplasms
fatigue
Lymphoma
vulnerability
Group
Breast Neoplasms
anxiety
Psychological Tests
Neuropsychological Tests
gender
ability
Proxy

ASJC Scopus subject areas

  • Oncology
  • Psychology(all)
  • Social Sciences (miscellaneous)

Cite this

The relationship of APOE genotype to neuropsychological performance in long-term cancer survivors treated with standard dose chemotherapy. / Ahles, Tim A.; Saykin, Andrew; Noll, Walter W.; Furstenberg, Charlotte T.; Guerin, Stephen; Cole, Bernard; Mott, Leila A.

In: Psycho-Oncology, Vol. 12, No. 6, 09.2003, p. 612-619.

Research output: Contribution to journalArticle

Ahles, Tim A. ; Saykin, Andrew ; Noll, Walter W. ; Furstenberg, Charlotte T. ; Guerin, Stephen ; Cole, Bernard ; Mott, Leila A. / The relationship of APOE genotype to neuropsychological performance in long-term cancer survivors treated with standard dose chemotherapy. In: Psycho-Oncology. 2003 ; Vol. 12, No. 6. pp. 612-619.
@article{287928f8d5f24f73944db30223a0a1df,
title = "The relationship of APOE genotype to neuropsychological performance in long-term cancer survivors treated with standard dose chemotherapy",
abstract = "Purpose: The primary purpose of this study was to compare the neuropsychological performance of long-term survivors of breast cancer and lymphoma treated with standard dose chemotherapy who carried the ε4 allele of the Apolipoprotein E (APOE) gene to those who carry other APOE alleles. Patients and methods: Long-term survivors (mean = 8.8 ± 4.3 years post-treatment) of breast cancer (N = 51, age = 55.9 ± 8.8) or lymphoma (N = 29, age = 55.8 ± 11.6) who had been treated with standard-dose chemotherapy completed a standardized battery of neuropsychological and psychological tests. Survivors were also classified into two groups based on the presence (N = 17) or absence (N = 63) of at least one ε4 allele of APOE. Results: Analysis of covariance, controlling for age, gender, education, diagnosis, and WRAT-3 reading subtest (a proxy measure of baseline IQ), indicated that survivors with at least one ε4 allele scored significantly lower in the visual memory (p <0.03) and the spatial ability (p <0.05) domains and tended to score lower in the psychomotor functioning (p <0.08) domain as compared to survivors who did not carry an ε4 allele. No group differences were found on depression, anxiety, or fatigue. Conclusions: The results of this study provide preliminary support for the hypothesis that the ε4 allele of APOE may be a potential genetic marker for increased vulnerability to chemotherapy-induced cognitive decline.",
author = "Ahles, {Tim A.} and Andrew Saykin and Noll, {Walter W.} and Furstenberg, {Charlotte T.} and Stephen Guerin and Bernard Cole and Mott, {Leila A.}",
year = "2003",
month = "9",
doi = "10.1002/pon.742",
language = "English (US)",
volume = "12",
pages = "612--619",
journal = "Psycho-Oncology",
issn = "1057-9249",
publisher = "John Wiley and Sons Ltd",
number = "6",

}

TY - JOUR

T1 - The relationship of APOE genotype to neuropsychological performance in long-term cancer survivors treated with standard dose chemotherapy

AU - Ahles, Tim A.

AU - Saykin, Andrew

AU - Noll, Walter W.

AU - Furstenberg, Charlotte T.

AU - Guerin, Stephen

AU - Cole, Bernard

AU - Mott, Leila A.

PY - 2003/9

Y1 - 2003/9

N2 - Purpose: The primary purpose of this study was to compare the neuropsychological performance of long-term survivors of breast cancer and lymphoma treated with standard dose chemotherapy who carried the ε4 allele of the Apolipoprotein E (APOE) gene to those who carry other APOE alleles. Patients and methods: Long-term survivors (mean = 8.8 ± 4.3 years post-treatment) of breast cancer (N = 51, age = 55.9 ± 8.8) or lymphoma (N = 29, age = 55.8 ± 11.6) who had been treated with standard-dose chemotherapy completed a standardized battery of neuropsychological and psychological tests. Survivors were also classified into two groups based on the presence (N = 17) or absence (N = 63) of at least one ε4 allele of APOE. Results: Analysis of covariance, controlling for age, gender, education, diagnosis, and WRAT-3 reading subtest (a proxy measure of baseline IQ), indicated that survivors with at least one ε4 allele scored significantly lower in the visual memory (p <0.03) and the spatial ability (p <0.05) domains and tended to score lower in the psychomotor functioning (p <0.08) domain as compared to survivors who did not carry an ε4 allele. No group differences were found on depression, anxiety, or fatigue. Conclusions: The results of this study provide preliminary support for the hypothesis that the ε4 allele of APOE may be a potential genetic marker for increased vulnerability to chemotherapy-induced cognitive decline.

AB - Purpose: The primary purpose of this study was to compare the neuropsychological performance of long-term survivors of breast cancer and lymphoma treated with standard dose chemotherapy who carried the ε4 allele of the Apolipoprotein E (APOE) gene to those who carry other APOE alleles. Patients and methods: Long-term survivors (mean = 8.8 ± 4.3 years post-treatment) of breast cancer (N = 51, age = 55.9 ± 8.8) or lymphoma (N = 29, age = 55.8 ± 11.6) who had been treated with standard-dose chemotherapy completed a standardized battery of neuropsychological and psychological tests. Survivors were also classified into two groups based on the presence (N = 17) or absence (N = 63) of at least one ε4 allele of APOE. Results: Analysis of covariance, controlling for age, gender, education, diagnosis, and WRAT-3 reading subtest (a proxy measure of baseline IQ), indicated that survivors with at least one ε4 allele scored significantly lower in the visual memory (p <0.03) and the spatial ability (p <0.05) domains and tended to score lower in the psychomotor functioning (p <0.08) domain as compared to survivors who did not carry an ε4 allele. No group differences were found on depression, anxiety, or fatigue. Conclusions: The results of this study provide preliminary support for the hypothesis that the ε4 allele of APOE may be a potential genetic marker for increased vulnerability to chemotherapy-induced cognitive decline.

UR - http://www.scopus.com/inward/record.url?scp=0042695788&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0042695788&partnerID=8YFLogxK

U2 - 10.1002/pon.742

DO - 10.1002/pon.742

M3 - Article

C2 - 12923801

AN - SCOPUS:0042695788

VL - 12

SP - 612

EP - 619

JO - Psycho-Oncology

JF - Psycho-Oncology

SN - 1057-9249

IS - 6

ER -